US Patent

US11179328 — Compositions and methods for the treatment of presbyopia

Method of Use · Assigned to Lenz Therapeutics Inc · Expires 2034-03-24 · 8y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant and a viscosity agent.

USPTO Abstract

The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant and a viscosity agent.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3741`	—

Patent Metadata

Patent number: US11179328
Jurisdiction: US
Classification: Method of Use
Expires: 2034-03-24
Drug substance claim: No
Drug product claim: No
Assignee: Lenz Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.